HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis
ConclusionHOXB5 may be a novel therapeutic target as an oncogenic driver by regulating EGFR transcription in HNSCC.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Epithelial Cancer | Genetics | Head and Neck Cancer | HNSCC | Skin Cancer | Squamous Cell Carcinoma | Surgery